SCHEMBL3011222

SCHEMBL3011222

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPK1 P28482 2/20 0.51
SMN1; SMN2 Q16637 8/20 0.45
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
MAPT P10636 5/20 0.45
CTSS P25774 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
FFAR2 O15552 1/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
FAAH O00519 1/20 0.43
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008381 0.93 LMNA (0.47) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3017077 0.93 LMNA (0.49) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3004717 0.89 SMN1; SMN2 (0.58) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3019657 0.89 MAPT (0.56) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3016062 0.89 LMNA (0.55) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3008132 0.89 SMN1; SMN2 (0.48) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3010403 0.89 SMN1; SMN2 (0.48) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3001742 0.89 MEN1 (0.51) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3020092 0.88 MAPT (0.48) LMNAMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3018188 0.87 SMN1; SMN2 (0.47) LMNAMEN1KMT2AMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.